Little is known about differences across ethnicities in the development of drug-induced liver injury (DILI) after highly active antiretroviral therapy (HAART) initiation. Methods: This is a retrospective, longitudinal, comparative, pilot study. DILI within the first year of HAART was evaluated in 50 HIV-infected Hispanics without viral hepatitis who initiated HAART between 2000 and 2009. It was compared to white and black patients (1:1:1) matched by age and CD4 counts. Results: HAART-related DILI of any grade occurred in 30 of 150 (20%) patients and was associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) use ). Severe DILI was significantly more frequent among Hispanics compared to other groups (6% vs. 0%; P ¼ .04). Of the 3 patients with severe DILI, 2 underwent liver imaging and had hepatic steatosis. Conclusions: Severe DILI within the first year of HAART initiation was infrequent and restricted to Hispanics. Additional studies are needed to determine if fatty liver is involved in the excess of severe DILI observed in this group.
Introduction
Drug induced liver injury (DILI) is one of the side effects of highly active antiretroviral therapy (HAART) in HIVinfected patients. Several mechanisms of HAART-related hepatotoxicity have been recognized. 1 Some data suggest a contribution of HAART to the development of a metabolic syndrome and liver steatosis which as a result can lead to liver injury. 2 Steatosis has been reported to be more frequent among Hispanics compared to other races. [3] [4] [5] It is unknown if this racial disparity translates into higher risk of DILI among Hispanics while receiving HAART.
Methods
This is a retrospective, longitudinal, comparative, pilot study performed at an academic tertiary hospital (Wake Forest University Baptist Medical Center, Winston Salem, North Carolina). It was approved by the institutional review board. The records of HIVinfected patients (as determined by ELISA and confirmed by Western blot) attending the WFUBMC HIV clinic were reviewed. Fifty consecutive Hispanics who had initiated a first HAART regimen between January 2000 and October 2009, with baseline and follow-up aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and compliant with the initial antiretroviral regimen for at least 6 months were identified. Patients with hepatitis B (HBV) or C virus (HCV) infection as determined by positive surface antigen and serum HCV RNA, respectively, were excluded. Two groups of equal size, one of African Americans and the other of white patients matched by age and CD4 counts were selected for comparison.
ALT and AST values, CD4 counts, and HIV RNA levels at baseline and at 3 months intervals were collected. Baseline age and weight were recorded as well. Information on alcohol intake was also obtained and categorized as abstainers (no alcohol intake), moderate (0-60 g per day), and heavy drinkers (greater than 60 g per day). Radiology reports with the terms hepatic steatosis or fatty liver in abdominal CT scan or ultrasound were included when available. Patients were followed for up to 1 year after HAART initiation. The upper limits of normal (ULN) for transaminases were defined using the American Association for the Study of Liver Disease with AST and ALT levels of 19 IU/L in women and of 30 IU/L in men. 6 In accordance with the AIDS Clinical Trials Group, patients with baseline normal values were considered to develop hepatotoxicity when ALT and/or AST rose above the ULN: grade 1 (1.25 À 2.5 Â ULN); grade 2 (2.6 À 5 Â ULN); grade 3 (5.1 À 10 Â ULN); and grade 4 (>10 Â ULN). 7 ALT/AST elevations were scored as grade 1 (1.25 À 2.5 Â baseline); grade 2 (2.6 À 3.5 Â baseline); grade 3 (3.6 À 5 Â baseline); and grade 4 (>5 Â baseline) in those with baseline abnormal values. 8 Data were reported as percentages for categorical and as median and range for continuous variables. Chi-square, Fisher exact, Student t, and ANOVA tests were used for intergroup comparisons.
Step-forward multivariate regression analyses for identification of DILI risk factors were also performed. P values <.05 defined statistical significance. SPSS (version 13.0, SPSS Inc, Chicago, Illinois) was used for all analyses.
Results
A total of 150 patients were included in the study: 50 Hispanics, 50 whites, and 50 blacks. The majority of the Hispanic patients were born in Mexico. All but one of the black patients were African Americans. Baseline characteristics of the patients according to race group are summarized in Table 1 . The characteristics of the patients were comparable among groups except for the proportion of females, which was highest among blacks. More white participants initiated nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens compared to the remaining groups. Patients were followed for a median time of 1 year. ALT levels were above the ULN in 77 of 150 (51.3%) patients at baseline. Forty-nine percent of those participants with abnormal baseline ALT endorsed alcohol use compared to 29% of those with ALT within normal limits (P ¼ .02).
DILI of any grade occurred in 30 of 150 (20%) within the follow-up period, with no differences across groups: Hispanic 9 of 50 (18%), white 10 of 50 (20%), and black 11 of 50 (22%). In univariate logistic regression analyses, NNRTI use was the only factor that predicted DILI of any grade (OR 4.64 [95% CI 1.52-14.13]; P ¼ .007). In a multivariate logistic regression analyses that included baseline CD4 counts (since it The incidence of grades 3-4 (severe) DILI was significantly higher among Hispanics (3/50, 6%) compared to white and black individuals (0%; P ¼ .04). The 3 patients denied alcohol intake and were not taking other potentially hepatotoxic medicines. Their demographics and additional clinical information including metabolic abnormalities are included in Table 2 . Patients #2 and #3 underwent a liver image study which in both cases suggested hepatic steatosis. Of note, the 3 patients had family history of diabetes mellitus.
Discussion
In this study of HIV-infected patients without viral hepatitis, DILI was relatively frequent but mild in most cases. NNRTI use, known by their hepatotoxic potential, was the only identified risk factor. 9,10 Of note, baseline ALT levels were above normal limits in more than half of patients. Although alternative causes could potentially explain baseline elevations, alcohol is likely an important factor since its use was significantly more frequently admitted by patients with abnormal ALT.
Severe DILI was an infrequent event (2% of the total sample studied) as expected in non-co-infected participants. 1, 8 However, a new finding in our study is the significantly higher risk of severe DILI among Hispanics. To our knowledge, this is the first report to identify an association between severe DILI and Hispanic ethnicity. The small size of the sample and low number of events preclude us from performing analysis to identify additional risk factors for severe DILI within that group. However, several clinical findings in those patients are worth to mention. All patients had impairment of the glucose metabolism and family history of diabetes mellitus. The 2 females underwent liver imaging which revealed hepatic steatosis. Unfortunately, we do not have available liver biopsy to confirm steatohepatitis as a cause of liver transminase elevation. However, the presence of metabolic abnormalities and family history make this possibility plausible. The late onset of severe DILI also favors a metabolic syndrome/steatosis as the cause rather than direct liver cell stress.
Nonalcoholic steatohepatitis (NASH) is the result of complex metabolic disturbances in which lipids and carbohydrates pathways are altered. 11 HAART has been shown to alter both metabolic systems. 12 Although HAART-related NASH has thus far not been defined as a specific entity, there are data supporting the contribution of HAART to the development of liver steatosis, which as a result can lead to inflammation and fibrosis. 2 Hyperglycemia, overweight, and insulin resistance have been associated with liver steatosis in treatment-experienced HIV-infected patients. 2, 13 Several studies assessing liver histopathology found NASH in more than half HAART-treated HIV-infected patients who underwent liver biopsy due to chronic unexplained transaminase elevation, some of them with lipodystrophy also. 2, 14, 15 Significant liver fibrosis, and even cirrhosis, has been recognized in some of those patients. 2 Hispanics have been found to have the highest prevalence of hepatic steatosis followed by Caucasians and then African Americans. [3] [4] [5] Moreover, Hispanics have a more severe form of steatosis and liver damage. 16 The underlying cause of these racial disparities is unknown, but the differences are not attributable to BMI, insulin resistance, or alcohol intake. 4 It is unknown if HAART would be a factor that could further increase the risk of steatohepatitis among Hispanics. Additional studies are warranted.
Our study has several limitations. The patients who developed severe DILI did not undergo liver biopsy to help to determine the cause of hypertransaminasemia. The small sample and low number of events preclude from identifying confounders using multivariate analyses. The information on metabolic parameters was limited with no universal data on lipid levels and insulin resistance. Liver image studies were only available for a small fraction of patients and therefore an association between higher prevalence of steatosis and of severe DILI incidence cannot be determined. Lastly, the short follow-up likely has caused an underestimation of the phenomenon since DILI related to metabolic changes might develop only after prolonged HAART use.
In summary, in this study performed in HIV-infected patients without viral hepatitis coinfection, severe DILI within the first year of HAART initiation was infrequent and restricted to Hispanics. Our limited data suggest that fatty liver disease might be involved in the excess of severe DILI observed in this group. Additional data are needed to determine if HAART use could contribute to the development/worsening of steatosis and liver injury among at-risk Hispanics. Abbreviations: ART, antiretroviral therapy; NNRT, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Mo, months; HgbA1c, hemoglobin A1c; Glu, serum glucose levels; TG, serum triglyceride levels.
